NDANASALSPRAY, METERED
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCENASE AQ is a metered-dose nasal spray containing beclomethasone dipropionate monohydrate, a corticosteroid approved by the FDA in 1996. It is indicated for allergic and non-allergic rhinitis, reducing nasal inflammation and symptoms in patients with chronic nasal conditions. The drug works by local anti-inflammatory action in the nasal mucosa.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), commercial teams face revenue defense and transition planning challenges.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss of exclusivity, VANCENASE AQ offers limited career advancement opportunities and represents a mature brand undergoing portfolio transition. Professionals on this product should anticipate restructuring and plan career moves to growth-stage franchises.
Brand ManagerField Sales Representative
Worked on VANCENASE AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.